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Abstract
CD40L is essential for the development of adaptive immune responses. It is generally thought that CD40L expression in
CD4
+ T cells is regulated transcriptionally and made from new mRNA following antigen recognition. However, imaging
studies show that the majority of cognate interactions between effector CD4
+ T cells and APCs in vivo are too short to allow
de novo CD40L synthesis. We previously showed that Th1 effector and memory cells store preformed CD40L (pCD40L) in
lysosomal compartments and mobilize it onto the plasma membrane immediately after antigenic stimulation, suggesting
that primed CD4
+ T cells may use pCD40L to activate APCs during brief encounters. Indeed, our recent study showed that
pCD40L is sufficient to mediate selective activation of cognate B cells and trigger DC activation in vitro. In this study, we
show that pCD40L is present in Th1 and follicular helper T cells developed during infection with lymphocytic
choriomeningitis virus, Th2 cells in the airway of asthmatic mice, and Th17 cells from the CNS of animals with experimental
autoimmune encephalitis (EAE). pCD40L is nearly absent in both natural and induced Treg cells, even in the presence of
intense inflammation such as occurs in EAE. We also found pCD40L expression in CD4 single positive thymocytes and
invariant NKT cells. Together, these results suggest that pCD40L may function in T cell development as well as an
unexpectedly broad spectrum of innate and adaptive immune responses, while its expression in Treg cells is repressed to
avoid compromising their suppressive activity.
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Introduction
T cell help for APCs is essential for adaptive immune responses
[1,2]. Effector CD4
+ T cells deliver help to antigen-specific B cells
in an MHC class II-restricted manner [3]. CD40L, a membrane-
bound cytokine in the TNF superfamily, plays a crucial role in this
process. CD40L is also required for generating optimal CD4
+ T
and CD8
+ T cell responses through activation of dendritic cells
(DCs) [4]. Thus, lack of CD40L expression causes defective
humoral and cellular immunity [5]. In contrast, dysregulated
CD40L expression causes autoimmunity, lymphoma, and prema-
ture termination of humoral immunity [6,7,8,9]. A recent clinical
trial of recombinant CD40L failed to restore B cell responses
whereas it successfully elicited Th1 responses in patients who
harbor mutations in the genes encoding CD40L [10]. A precise
understanding of CD40L regulation, including its expression and
manner of delivery, could assist in the development of effective
vaccines, immunological interventions for inflammatory diseases,
and successful treatment of CD40L deficient patients.
It is generally thought that CD40L is synthesized from new
mRNA (de novo CD40L) and delivered while effector CD4
+ T
cells are engaged in intimate interactions with cognate APCs in the
time frame of a few hours [11]. This notion has been challenged
by studies utilizing two-photon microscopy. While the initial,
stable interactions of naı ¨ve CD4
+ T cells and DCs can last for
several hours, the majority of interactions between effector CD4
+
T cells and cognate APCs in vivo are surprisingly short, ranging
from several minutes up to 30 minutes [12,13,14,15]. Although
these short interactions are antigen-specific and presumed to be
productive, 30 minutes is not enough time for effector CD4
+ T
cells to make de novo CD40L.
We propose that effector CD4
+ T cells activate cognate APCs
during brief interactions using preformed CD40L (pCD40L). We
and others have demonstrated that human and mouse effector and
resting memory CD4
+ T cells retain pCD40L intracellularly, and
that pCD40L can come to the cell surface within a few minutes of
antigenic stimulation [16,17]. Th1 cells store pCD40L in
lysosome-related organelles known as secretory lysosomes [17], a
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containing perforin and granzyme B in cytotoxic T-lymphocytes
(CTLs) and natural killer (NK) cells [18]. The existence of
cytotoxic Th1 cells in humans and mice which resemble CD8
+
CTLs in function also supports the idea of antigen-specific
execution of CD4
+ T cell effector functions by controlled,
directional secretion of preformed effector molecules through
delivery of secretory compartment to the immunological synapse
[19,20,21]. In fact, our recent study demonstrates that pCD40L is
sufficient to mediate selective activation of cognate B cells and
trigger DC activation in vitro [22].
Many subsets of effector CD4
+ T cells have been described: Th1
cells control intracellular pathogens, Th2 cells contain extracellu-
lar parasites, Th17 cells counteract extracellular bacteria and
fungi, T follicular helper (TFH) cells promote antibody production,
and regulatory T (Treg) cells prevent uncontrolled tissue damage
by dampening APC activation [23]. Although other groups have
reported selective expression of pCD40L in certain subsets of
effector CD4
+ T cells in disease states and healthy animals
[16,17,24,25,26,27,28], this report is the first to systematically
examine surface mobilization of pCD40L in each subset of effector
CD4
+ T cells and Treg cells, using physiologically relevant
antigen-pulsed APCs to trigger surface mobilization in an effort to
shed light on the role of pCD40L in vivo.
In the present study, we investigated TCR-regulated surface
expression of pCD40L in Th1, Th2, Th17, and TFH cells,
thymocytes, invariant natural killer T (iNKT) cells and Treg cells.
Our results show that pCD40L is stored in all tested subsets of
effector CD4
+ T cells from lymphoid organs and non-lymphoid
effector sites as well as CD4 single positive (SP) thymocytes and
iNKT cells, but is undetectable or nearly undetectable in natural
or induced Treg cells, NK cells, or CD8
+ T cells. These results
provide the first comprehensive description of cells that store and
mobilize pCD40L in vivo, and suggest that pCD40L may function
in CD4
+ T cell development and a broad range of immune
responses in vivo.
Materials and Methods
Mice
Mice were housed under specific pathogen–free conditions.
These studies were approved by the Institutional Animal Care and
Use Committee at Oregon Health & Science University. BALB/c,
C57BL/6, DO11.10, Cd40lg
2/2, b2m
2/2, and IL-4/enhanced
GFP reporter (4get) mice were from the Jackson Laboratory (Bar
Harbor, ME). DO11.10 Rag2
2/2 and BALB/c nu/nu mice were
obtained from Taconic Farms (Germantown, NY). 4get/DO11.10
mice were bred in-house. SMARTA mice were obtained from Dr.
J. Lindsay Whitton (The Scripps Research Institute).
Antibodies and reagents
Biotin–anti-CXCR5 was purchased from BD Biosciences (San
Jose, CA). FITC-anti-T1/ST2 was purchased from MD Biosci-
ences (Saint Paul, MN). Allophycocyanin-labeled tetramers
consisting of CD1d folded with PBS57 were provided by the
NIH Tetramer Core Facility (Atlanta, GA). All other antibodies
for flow cytometry were purchased from eBioscience (San Diego,
CA). The Foxp3 staining kit was purchased from Biolegend (San
Diego, CA). Recombinant cytokines were purchased from
Peprotech (Rocky Hill, NJ). Anti-IFN-c and anti-IL-4 were from
Bio X Cell (West Lebanon, NH). Papain was from Calbiochem
(San Diego, CA). Endotoxin-free ovalbumin (OVA) protein was
from Profos AG (Regensburg, Germany). OVA peptide (323–339)
was from AnaSpec, Inc. (Fremont, CA). All-trans retinoic acid,
BSA, OVA protein, PMA and ionomycin were from Sigma-
Aldrich (St Louis, MO).
T cell differentiation in vitro
Th1, Th2, and Th17 cells were prepared by culturing spleen
cells from DO11.10 mice in the presence of 1 mM of antigenic
peptide (OVA 323–339) for 4 days with combinations of cytokines
and antibodies as follows: Th1: 1 ng/ml IL-12 and 10 mg/ml anti-
IL-4; Th2: 10 mg/ml anti-IFN-c and 100 ng/ml IL-4; Th17:
20 mg/ml anti-IFN-c,2 0 mg/ml anti-IL-4, 20 mg/ml anti-IL-2,
100 ng/ml IL-6, 5 ng/ml human TGF-b1, 20 ng/ml IL-1b, and
20 ng/ml TNF-a. Differentiation of Th1, Th2, and Th17 cells was
confirmed by intracellular cytokine staining of IFN-c, IL-4, and
IL-17A upon 5 hour stimulation with PMA plus ionomycin in the
presence of brefeldin A using the Cytofix/Cytoperm kit from BD
Biosciences (data not shown). In some experiments, Th2 cells were
restimulated with antigen-pulsed purified B cells in the absence or
presence of recombinant IL-4 or anti-IL-4 for 4 days. Stability of
Th2 cells after the second round of proliferation was assessed by
FACS analysis of IL-4/eGFP levels and by detection of IL-4 in the
culture media with ELISA kits (BD Biosciences). To obtain
induced Treg (iTreg) cells, DO11.10 cells and B cells were purified
with EasySep mouse CD4
+ T cell enrichment and B cell
enrichment kits (Stemcell Technologies: Vancouver, Canada),
respectively, and were co-cultured in the presence of 1 mM
antigenic peptide, 100 U/ml IL-2, 20 ng/ml TGF-b, and 10 nM
all-trans retinoic acid for 4 days [29].
Lymphocytic choriomeningitis virus (LCMV) infection
To obtain in vivo-generated Th1 cells, spleen cells were
prepared from recipient C57BL/6 mice that had been given
2610
4 spleen cells from SMARTA mice followed by i.p. infection
with 2610
5 PFU of LCMV (Armstrong 53b strain) [17]. To assess
endogenous, polyclonal Th1 and TFH cells, spleen cells were
harvested 12 days after LCMV infection.
Papain plus OVA immunization
To obtain in vivo-generated Th2 and TFH cells, one million
4get/DO11.10 cells (CD25-depleted, .95% purity) were trans-
ferred into BALB/c mice. The next day, recipients were
immunized subcutaneously with papain (50 mg) plus endotoxin-
free OVA protein (50 mg) [30]. On day 7, Th2 and TFH cells from
draining lymph nodes (dLNs) were prepared for flow cytometric
analysis.
Asthma model
To obtain polyclonal Th2 cells, C57BL/6 mice were sensitized
twice by i.p. injection of OVA protein emulsified in aluminum
hydroxide (Pierce, Rockford, IL) and challenged intratracheally
with OVA protein/PBS three times. Mice were sacrificed,
tracheas were cannulated, and lungs were lavaged three times
with 0.5 ml PBS per wash to obtain bronchoalveolar lavage fluid
(BALF) cells [31].
Experimental autoimmune encephalomyelitis (EAE)
model
For analysis of in vivo-generated Th17 cells and Treg cells from
an inflammatory site, active EAE was induced and CNS
infiltrating leukocytes were obtained as described [32]. Briefly,
C57BL/6 mice were immunized by subcutaneous injection in the
lower back with 200 mg myelin oligodendrocyte glycoprotein
(MOG)35–55 (MEVGWYRSPFSRVVHLYRNGK) peptide
emulsified at a 1:1 ratio with complete Freund’s adjuvant
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MI). Pertussis toxin (List Biological Laboratories, Campbell CA)
was administered on day 0 (200 ng) and day +2 (200 ng) with
respect to the immunization day. Only symptomatic mice were
used at 14 days after immunization.
Oral tolerance model
In vivo-generated iTreg cells were prepared from mesenteric
LNs of BALB/c nu/nu recipients which had received i.v. injection
of 5610
5 naive CD4
+ T cells purified from DO11.10 Rag2
2/2
mice followed by feeding with BSA- or OVA-containing water for
6 days. [33].
Flow cytometry for detection of pCD40L
The surface mobilization assay and intracellular staining were
described previously [17] and are explained at the beginning of the
Results section. To detect pCD40L in Th17 cells generated in
vivo, CNS infiltrating leukocytes from EAE animals were analyzed
by the CD40L mobilization assay followed by intracellular
cytokine staining. Cells were incubated in the presence or absence
of MOG peptide-pulsed APCs with either isotype-PE or PE-
labeled anti-CD40L at 37uC for 30 minutes. After washes, cells
were incubated for 4.5 hours in the presence of brefeldin A and
MOG peptide-pulsed APCs. After fixation, intracellular IL-17A
and IFN-c were stained. Data were obtained with an LSR II (BD
Biosciences) and analyzed with FlowJo software (Tree Star, Inc.,
Ashland, OR).
Results
Detecting pCD40L using the mobilization assay and
intracellular staining
We previously reported successful use of the mobilization assay
and intracellular staining to assess existence of pCD40L in Th1
effector and memory cells as well as memory-phenotype CD4
+ T
cells [17,22]. It has been reported that CD40 engagement induces
CD40L internalization [34] and that inhibition of CD40-CD40L
engagement with blocking anti-CD40L increases CD40L detec-
tion [35]. In the mobilization assay, fluorochrome-labeled anti-
CD40L mAb is included in the culture at 37uC in the presence or
absence of stimulation. Compared to the ‘‘snap shot’’ nature of
conventional staining at 4uC after completion of stimulation, the
mobilization assay provides the ‘‘long exposure’’ view of CD40L
surface expression by capturing and stabilizing CD40L that has
been delivered to the cell surface during incubation (Fig. S1)
[36,37]. We found negligible amounts of pre-existing surface
CD40L on resting effector CD4
+ T cells [17]. By limiting the
stimulation period to 30 minutes, we were able to exclude surface
expression of de-novo CD40L made following stimulation.
Although a contribution of new CD40L protein expression from
stable pre-existing CD40L mRNA cannot be fully excluded by
limiting the assay to 30 minutes [38], we showed in a previous
report with T effectors that complete inhibition of protein
synthesis did not diminish surface expression of CD40L following
30 minutes of stimulation [17]. Intracellular staining can be seen
as an ‘‘x-ray’’, and could distinguish defective mobilization of
pCD40L from absence of stored pCD40L in cases where no
mobilization of pCD40L is observed.
In vitro-generated Th1 and Th17, but not Th2 or iTreg
cells, store and mobilize pCD40L upon stimulation
We previously showed that effector and resting memory Th1
cells, differentiated either in vitro or in vivo, store intracellular
pCD40L and mobilize it to the cell surface within 30 minutes of
stimulation [17]. A finding that pCD40L is stored in certain Th
subsets would suggest that pCD40L serves in defined immune
responses, just as signature cytokines do. Therefore, we examined
the distribution of pCD40L among subsets of effector CD4
+ T
cells and Treg cells.
We generated Th1, Th2, Th17, and iTreg cells in vitro and
measured pCD40L. While Th1 and Th17 cells clearly mobilize
pCD40L, Th2 cells mobilize much less pCD40L (Fig. 1A) and
possess significantly less intracellular CD40L (Fig. 1C). pCD40L is
at the limit of detection in iTreg cells (Figs. 1A, 1C). The decreased
surface mobilization in Th2 cells, and the near absence of
pCD40L in Treg cells, are not due to suboptimal stimulation or
permeabilization of these cells because Th2 and iTreg cells possess
and mobilize preformed CTLA-4 at the same level as Th1 and
Th17 cells (Figs. 1B, 1D).
In vivo-generated Th1 and TFH cells possess and mobilize
pCD40L upon antigenic stimulation
To further characterize the involvement of pCD40L in vivo, we
examined effector CD4
+ T cell subsets generated in vivo.
SMARTA CD4
+ T cells, which have a transgenic TCR specific
for an LCMV epitope [39], were transferred into normal mice
followed by infection with LCMV (Fig. 2A). Th1 differentiation of
these cells was confirmed by intracellular staining of IFN-c upon in
vitro stimulation with PMA plus ionomycin (60–70% IFN-c
+, data
not shown). The mobilization assay shows that in vivo-generated
Th1 SMARTA (CD4
+Va2
+Vb8.3
+, Fig. 2B) cells mobilize
pCD40L in an antigen-specific manner (Fig. 2C). SMARTA cells
expanded during LCMV infection were reported to contain both
Th1 and TFH cells [40]. To rule out the possibility of preferential
pCD40L expression in TFH cells rather than Th1 cells,
mobilization of pCD40L was assessed in endogenous polyclonal
TFH cells (CD4
+CD44
hiCXCR5
hiPD-1
hi) and Th1 cells
(CD4
+CD44
hiCXCR5
lowPD-1
low) from spleens of LCMV-infected
mice (Figs. 2D, 2E). The result shows that both Th1 and TFH cells
mobilize pCD40L upon stimulation (Fig. 2F).
In vivo-generated Th2 cells possess and mobilize pCD40L
upon antigenic stimulation
Next, we tested in vivo-generated Th2 cells by transferring
CD4
+ T cells from 4get/DO11.10 TCR transgenic mice into
normal mice and immunizing recipients with papain plus OVA
protein, which induces a robust Th2 response in vivo [30] (Fig. 3A).
A week after immunization, 20 to 40% of the DO11.10 CD4
+ T
cells became IL-4/eGFP positive Th2 cells (Fig. 3B and data not
shown). In contrast to what we observed with in vitro-generated
Th2 cells, in vivo-generated Th2 cells mobilize a substantial
amount of pCD40L upon cognate interactions with APCs (Fig. 3C).
To rule out the possibility of preferential pCD40L expression in
TFH cells rather than in Th2 cells, we conducted the mobilization
assay for pCD40L followed by staining of CXCR5 and PD-1
[26,41]. The mobilization assay shows that both TFH (IL-4/
eGFP
+CXCR5
hiPD-1
hi) and Th2 (IL-4/eGFP
+CXCR5
lowPD-
1
low) DO11.10 cells mobilize pCD40L (Figs. 3D, 3E). To further
verify these findings, we analyzed endogenous, polyclonal Th2
cells in an asthma model (Fig. 3F). We observed mobilization of
pCD40L in polyclonal Th2 cells, which were identified by a Th2
marker (T1/ST2, IL-33R), in BALF from sensitized and
challenged animals (Figs. 3G, 3H) [42]. These results were
surprising since in vitro-generated Th2 cells stored and mobilized
very little pCD40L. To determine the root of this discrepancy, we
considered cell-extrinsic factors that might downregulate pCD40L
T Cell Storage and Mobilization of Preformed CD40L
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repress the late phase of de novo CD40L expression by stimulated
naı ¨ve CD4
+ T cells [43], we tested whether exogenous or
accumulated IL-4 in the culture is responsible for the diminished
pCD40L expression in Th2 cells. In vitro-generated Th2 cells were
prepared as in Fig. 1 and then restimulated with antigen-pulsed
APCs either in the absence or presence of recombinant IL-4 or
neutralizing anti-IL-4 for 4 days. After the two rounds of
stimulation, all groups of Th2 cells maintained their stable Th2
phenotypeasmeasuredbyIL-4/eGFP expression (Fig. 4A) and IL-4
protein secretion upon PMA plus ionomycin stimulation (Fig. 4B).
When the three groups of Th2 cells were analyzed, we found that
only Th2 cells that underwent the second round of stimulation in
the presence of anti-IL-4 mobilized pCD40L upon stimulation
(Fig. 4C). These data indicate that a non-physiological level of IL-4
inthe invitroculture causesdownregulation ofpCD40L. IL-4levels
Figure 1. In vitro-generated Th1 and Th17, but not Th2 or iTreg cells mobilize pCD40L. A and B, Mobilization assay. In vitro-generated
Th1, Th2, Th17, and iTreg cells were stimulated with PMA plus ionomycin or left unstimulated in the presence of PE-isotype Ab, PE-anti-CD40L or PE-
anti-CTLA-4 at 37uC for 30 minutes. The levels of CD40L (A) and CTLA-4 (B) are shown. C and D, Intracellular staining. Cells were fixed without
stimulation, permeabilized, and stained with PE-isotype Ab, PE-anti-CD40L or PE-anti-CTLA-4. The levels of CD40L (C) and CTLA-4 (D) are shown. Data
are representative of five independent experiments.
doi:10.1371/journal.pone.0031296.g001
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estimated to be 15–500 pg/ml [44], whereas the culture media in
this experiment may contain 5–100 ng/ml of IL-4. We conclude
that Th2 cellsdo store and mobilize pCD40Lexceptinthe presence
of high levels of exogenous or accumulated IL-4.
In vivo-generated Th17 cells possess and mobilize
pCD40L upon antigenic stimulation
We also tested in vivo-generated Th17 cells for pCD40L using
an EAE model (Fig. 5A). To distinguish Th17 cells from Th17/
Th1 and Th1 cells in the mobilization assay, cells from the CNS of
symptomatic EAE animals were analyzed with a combination of
intracellular cytokine staining and the mobilization assay (Fig. 5B).
Endogenous Th17 cells, as well as Th17/Th1 and Th1 cells, but
not antigen non-specific (IFN-c
2IL-17A
2) CD4
+ T cells from
EAE lesions mobilize pCD40L upon antigen recognition (Figs. 5C,
5D). Together, the findings above show that pCD40L is widely
shared among effector CD4
+ T cells.
Treg cells possess little or no pCD40L
Although Treg cells are reported to accumulate low levels of
surface CD40L in the steady state in CD40
2/2 mice [45], we
observed little or no pCD40L in iTreg cells generated in vitro
(Fig. 1). We observed differences in pCD40L level between in vitro
and in vivo Th2 cells (Figs. 1, 3, and 4), leading us to examine
pCD40L expression and mobilization in Treg cells obtained in
vivo. We were unable to detect unambiguous pCD40L expression
in either thymic natural Treg (nTreg) cells or splenic Treg cells
from unmanipulated mice, although they both express and
mobilize CTLA-4 (Figs. 6A, 6D and Figs. S2A,S 2 B). In accord
with this notion, exclusion of CD44
hi nTreg cells from memory
phenotype (MP) CD4
+ T cells resulted in higher pCD40L
mobilization than previously reported [17] (Figs. S2A,S 2 C).
Although we previously concluded that naı ¨ve CD4
+ T cells do not
have pCD40L [17], we reproducibly detected a very low level of
pCD40L in naı ¨ve CD4
+ T cells (Figs. S2A,S 2 D). Low level
pCD40L expression in naı ¨ve CD4
+ T cells has also been reported
by others [28].
Next, we tested antigen-driven, in vivo-generated iTreg cells
induced in an oral tolerance model with OVA [33] (Figs. 6B, 6C).
Although it has been shown that CD40L is required for the
induction of oral tolerance [46], we found that in vivo-generated
iTreg cells nearly lack pCD40L expression (Fig. 6F), while the
CD44
hi effector CD4
+ T cells in the same model had a high level
Figure 2. In vivo-generated Th1 and TFH cells possess and mobilize pCD40L. A, Generation of antigen-specific Th1 cells. LCMV-glycoprotein-
specific, TCR-transgenic SMARTA CD4
+ T cells were recovered from LCMV-infected mice on day 8 post-infection. B, Gating strategy for SMARTA cells
(Va2
+,V b8.3
+). C, Mobilization of pCD40L by SMARTA cells in response to PMA plus ionomycin or the LCMV peptide gp67-pulsed APC. D, Polyclonal
Th1 and TFH cells. Spleen cells were obtained from LCMV-infected mice on day 12 post-infection. E, Gating strategy for TFH (CD4
+CD44
hiCXCR5
hiPD-
1
hi) and Th1 (CD4
+CD44
hiCXCR5
lowPD-1
low) cells. F, Mobilization of pCD40L by TFH and Th1 cells in response to PMA plus ionomycin. Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0031296.g002
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tolerogenic environment, we next examined whether Treg cells
might acquire pCD40L in an inflammatory environment. In EAE,
most Treg cells in inflamed CNS tissue are nTreg cells of thymic
origin [47]. Even though almost all Treg cells in the CNS
upregulate CD44 (Fig. 7A) and effector CD4
+ T cells acquire
abundant pCD40L (Fig. 7B), Treg cells from inflamed CNS as well
as spleens lacked detectable pCD40L (Fig. 7C). Taken together,
these data indicate that pCD40L expression in Treg cells is tightly
suppressed.
CD4 SP thymocytes and iNKT cells possess pCD40L
We were surprised to see low level pCD40L expression in
peripheral naı ¨ve CD4
+ T cells. This suggested to us that there
might be a developmental role for pCD40L, so we decided to
examine pCD40L in thymic T cell populations. When we looked
in the thymus, we found that CD4 SP (CD4
+CD8
2Foxp3
2)
thymocytes express and mobilize pCD40L (Fig. 6E). Further
analysis showed that immature CD4 SP thymocytes have more
pCD40L than mature CD4 SP thymocytes (Figs. 8A, B, C). We
could not detect any CD40L staining in CD4
2CD8
+ (CD8 SP)
Figure 3. In vivo-generated Th2 cells store and mobilize pCD40L. A, BALB/c mice that had received 4get/DO11.10 CD4
+ T cells were
subcutaneously immunized with papain plus OVA protein. Seven days later, cells from dLNs were analyzed by the mobilization assay. B, Gating
strategy for antigen-specific IL-4/eGFP
+ DO11.10 cells (CD4
+IL-4/eGFP
+KJ1-26
+). C, Mobilization of pCD40L by IL-4/eGFP
+ DO11.10 cells in response to
PMA plus ionomycin or OVA peptide-pulsed APC. D, Those cells were further differentiated as TFH (CXCR5
hiPD-1
hi) and Th2 (CXCR5
lowPD-1
low) cells. E,
Mobilization of pCD40L by TFH and Th2 cells in response to PMA plus ionomycin. F, To obtain polyclonal Th2 cells, mice were sensitized with OVA/
alum followed by intratracheal challenge with OVA/PBS. G, The gating strategy for Th2 cells (CD4
+T1/ST2
+) and non-Th2 cells in BALF. H, Mobilization
of pCD40L by polyclonal Th2 and non-Th2 cells in response to PMA plus ionomycin. Data are representative of two to three independent
experiments.
doi:10.1371/journal.pone.0031296.g003
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+CD8
+ double-positive (DP) thymocytes (Figs. 8D, 8E).
These results suggest that immature CD4 SP thymocytes acquire
pCD40L, and then decrease pCD40L to lower levels as they
mature.
We also detected mobilization of pCD40L in a small fraction of
the CD4
2CD8
2 double-negative (DN) population (Fig. 9A).
Further analysis showed that those cells were CD44
hi, TCR-b
int,
and CD1d-PBS57 tetramer positive iNKT cells (Fig. 9B). In fact,
in b2m-deficient (b2m
2/2) mice, which lack both CD8
+ T cells
and iNKT cells, the pCD40L positive population in DN
thymocytes is absent (Fig. 9C). Direct assessment of thymic iNKT
cells shows clear and uniform mobilization of pCD40L (Figs. 9D,
9E). Splenic iNKT had somewhat reduced pCD40L (Figs. 9F, 9G).
We found no detectable pCD40L in NK cells and CD8
+ T cells
(Figs. S3A,S 3 B) [17,48].
Discussion
Recent two-photon microscopy studies indicate that interactions
between effector CD4
+ T cells and APCs in vivo are surprisingly
brief [12,13,14,15], necessitating a reassessment of our ideas about
how CD4
+ T cells deliver their effector functions. The dominant
idea is directional secretion of newly synthesized cytokines toward
antigen-bearing APCs [49], but de novo cytokine synthesis
requires more time than is provided by these short in vivo
interactions. On the other hand, preformed effector molecules
stored in T cells can be delivered by regulated secretion in minutes
as opposed to hours. As a membrane-bound cytokine, CD40L is
designed for delivery by cell contact, and is necessary for cognate
help for B cells and licensing of DC [1,2], so regulated surface
expression of pCD40L could explain antigen-specific activation of
APC in brief interactions with CD4
+ T cells in vivo. pCD40L has
been reported in CD4
+ T cells [16,17,24,25,26,27,28], but it is not
yet known which functions of CD40L require de novo CD40L
synthesis and which can be supplied by pCD40L. Our recent study
showed that pCD40L is sufficient for the activation of DCs and
selective activation of antigen-bearing B cells in vitro [22]. In this
paper, we assessed possession and surface mobilization of pCD40L
among the newly expanded classification of CD4
+ T cell subsets by
signature cytokines [23] to determine whether pCD40L is
restricted to specific subsets with certain functions, for example,
TFH or Th1 cells. We found instead that pCD40L is expressed and
mobilized to the cell surface in all tested effector CD4
+ T cell
subsets, as well as CD4 SP thymocytes and iNKT cells. However,
neither nTreg nor iTreg cells possess easily detectable pCD40L.
Taken together, our recent findings indicate that pCD40L may be
involved in T cell development and function broadly in innate and
adaptive immunity.
pCD40L may also contribute to the pathology of inflammatory
diseases because pCD40L is not limited to the primary and
secondary lymphoid organs. Th2 cells recovered from the airway
of a mouse asthma model and Th1 and Th17 cells from CNS
disease lesions of EAE animals possess and mobilize pCD40L.
Similar findings were reported in effector CD4
+ T cells recovered
from synovial fluid of human rheumatoid arthritis patients [24]. It
has been shown that anti-CD40L treatment not only blocks the
induction phase but also ameliorates the effector phase of EAE
[50,51]. Two-photon microscopy shows predominantly brief
interactions of effector memory CD4
+ T cells with APCs in target
tissues [14]. Together, these findings suggest that pCD40L may
function during the effector phase of inflammation through the
promotion of cytokine secretion by APCs.
Strikingly, we found that only Treg cells lack reproducibly
detectable pCD40L among all CD4
+ T cells, further suggesting
that activation of APCs is the primary role of pCD40L. In
contrast, it has been reported that a fraction of Treg cells express
de novo CD40L upon activation [52] and elicit CD8 T cell
responses in a CD40L-dependent manner in vivo [53]. These
cases can be seen as functional reprogramming of Treg cells to
manifest helper/effector activity [54]. Therefore, one might
imagine that aberrant pCD40L expression in Treg cells could be
observed in severe inflammation. However, Treg cells defined by
Figure 4. Excess IL-4 downregulates pCD40L levels in Th2 cells
generated in vitro. Recovery of pCD40L in Th2 cells by neutralizing
IL-4. A–C, Differentiated Th2 cells from 4get/DO11.10 spleen cells were
restimulated with peptide-pulsed splenic APCs alone (Th2 2u) or in the
presence of exogenous IL-4 (Th2 2u plus IL-4) or anti-IL-4 (Th2 2u plus
anti-IL-4) for 4 days. A, The levels of IL-4/eGFP in each group of Th2 cells
as well as Th1 negative control cells. B, IL-4 production upon PMA plus
ionomycin stimulation by each group of Th2 cells was analyzed by
ELISA. Each bar represents the mean 6 standard deviation for
triplicates. C, Mobilization of pCD40L by each group of Th2 cells in
response to PMA plus ionomycin. Data are representative of two
independent experiments.
doi:10.1371/journal.pone.0031296.g004
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in the presence of pathologic inflammation caused by Th1 and
Th17 cells in EAE lesions, in keeping with a recent report that
showed an extremely stable phenotype of Treg cells [55].
Alternatively, ex-Treg cells that have lost Foxp3 expression might
gain pCD40L after conversion to aggressive effector CD4
+ T cells
[56]. In fact, converted ex-nTreg cells in the gut preferentially
become TFH cells and express CD40L [57]. Based on the above
findings, it would be interesting to test whether engineering Treg
cell-specific expression of pCD40L could redirect their activity
from regulation to activation of APCs.
There are several non-mutually exclusive mechanisms that
could explain the lack of pCD40L in Treg cells. One possibility is
transcriptional repression. It was shown that Foxp3 can form a
heterodimer with NFAT1, and that the NFAT1:Foxp3 complex
prevents the NFAT1:AP-1 complex from binding to the IL-2
promoter, resulting in repression of IL-2 mRNA transcription
[58]. The CD40L promoter has a consensus sequence (59-
GGAANNNNTGTTT-39) for the NFAT1:Foxp3 complex [58],
suggesting repression of CD40L mRNA transcription by the
NFAT1:Foxp3 complex. In fact, a reduced level of CD40L mRNA
was found in Treg cells compared to naı ¨ve CD4
+ T cells [45].
CD4
+ T cells from Foxp3 transgenic mice also showed reduced
CD40L expression upon anti-CD3 plus anti-CD28 stimulation
[59]. Independent of Foxp3, anergic CD4
+ T cells produced by
TCR stimulation without costimulation, presumably through
NFAT in the absence of AP-1 [60], also lack CD40L expression
[61,62]. Our preliminary data indicate that type 1 regulatory T
(Tr1) cells [63] lack pCD40L, strengthening the link between
diminished pCD40L and an anergic phenotype (Y. Koguchi, D.C.
Parker, unpublished data). Post-transcriptional regulation of
CD40L mRNA may be different between effector CD4
+ T cells
and Treg cells because CD40L mRNA is stabilized in response to
Ag recognition in effector T cells [64]. Another possibility is post-
translational modification of pCD40L. It is reported that GRAIL
(gene related to anergy in lymphocytes) directly downregulates
CD40L through its E3 ubiquitin ligase activity [65], although this
finding is controversial since GRAIL-deficient mice from two
different groups did not show any evidence of CD40L overex-
pression [66,67]. Investigation of the cause(s) of the lack of
pCD40L in Treg cells could shed light on how effector CD4
+ T
cells acquire and regulate pCD40L.
The selective expression of pCD40L in CD4 SP thymocytes
implies a role in T cell development. Through a careful
examination of pCD40L in thymocytes, we found that CD4 SP
thymocytes have pCD40L and immature CD4 SP thymocytes
have more pCD40L than mature CD4 SP thymocytes. CD40L is
necessary for thymic negative selection to endogenous superanti-
gens [68] and contributes to the maintenance of medullary thymic
epithelial cells (mTECs) [69,70,71]. Unregulated expression of
surface CD40L on thymocytes in CD40L transgenic mice caused
hyper-proliferation of mTECs [6]. Therefore, it seems likely that
regulated provision of pCD40L by CD4 SP thymocytes plays an
important role in homeostasis of mTECs. Provision of pCD40L by
CD4 SP thymocytes may also be important for homeostasis of
Treg cells by promoting IL-2 production from DCs [72].
Figure 5. In vivo-generated Th17 and Th17/Th1 cells store and mobilize pCD40L. A, CNS infiltrating leukocytes were obtained from brains
and spinal cords of EAE animals induced by immunization with CFA plus MOG peptide and pertussis toxin. B, CNS infiltrating leukocytes were
analyzed by the CD40L mobilization assay followed by intracellular cytokine staining. C, Intracellular staining of IL-17A and IFN-c in CNS CD4
+ T cells.
D, CD40L mobilization in Th1 (IL-17A
2IFN-c
+), Th17 (IL-17A
+IFN-c
2), Th17/Th1 (IL-17A
+IFN-c
+), and antigen non-specific (IL-17A
2IFN-c
2) CD4
+ T cells
upon antigenic stimulation. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0031296.g005
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31296iNKT cells, as innate immune cells, produce proinflammatory
and immunoregulatory cytokines and deliver effector functions
that depend on perforin and granzyme B [73]. Although de novo
CD40L expression in iNKT cells has been reported [74,75,76],
this is the first report of the presence of pCD40L in iNKT cells.
The contribution of CD40L to iNKT cell development has not
been studied. Although it is still a matter of debate, CD1d
expressing thymic DCs may mediate negative selection of iNKT
cells [77], in which case, pCD40L may play a role in that process.
In the periphery, iNKT cells can mediate acute hepatitis in
response to Con A in a CD40L-dependent manner [78], and
provide cognate help for iNKT glycolipid-pulsed B cells via
delivery of CD40L [79,80]. iNKT cells can license DCs and
myeloid-derived suppressor cells via delivery of CD40L for
optimal CD4
+ and CD8
+ T cell responses [81,82,83]. A recent
study using two-photon microscopy showed that cognate interac-
tions between lymph node macrophages and iNKT cells are
relatively stable (only 20% show short interaction less than 20 min)
[84] allowing ample time for de novo CD40L production.
Whether cognate interactions of iNKT cells with DCs and B cells
are stable or transient is currently unknown. Further studies are
required to address whether iNKT cells mobilize pCD40L upon
stimulation with glycolipid-pulsed APCs and whether any of the
CD40L-dependent functions of iNKT cells are owing to pCD40L.
The ability of pCD40L to be rapidly mobilized to the cell
surface upon antigen recognition provides a mechanism for T cells
to activate cognate APC during transient, antigen-specific
interactions in vivo. The broad distribution of pCD40L among
CD4
+ T effector cell subsets and iNKT cells indicates that use of
pCD40L may be widespread in T cell development and innate
and adaptive immune responses. Future research to define the
molecular machinery that regulates the formation of the pCD40L
secretory compartment and its delivery to the cell surface will
allow studies in vivo to determine which of the many known
functions of CD40L are owing to pCD40L, and provide new
targets for therapeutic intervention in inflammatory diseases.
Supporting Information
Figure S1 Schematic explanation of the mobilization
assay. In the mobilization assay, fluorochrome-labeled anti-
CD40L mAb is included in the culture during the activation of
cells at 37uC. Compared to the ‘‘snap shot’’ nature of conventional
staining at 4uC after completion of stimulation, the mobilization
assay captures CD40L that has been delivered to the cell surface
during stimulation while blocking CD40-dependent internaliza-
tion, thereby providing the ‘‘long exposure’’ view of CD40L
surface expression. By limiting the stimulation period to
30 minutes, we were able to exclude surface expression of de-
novo CD40L made following stimulation (Koguchi, 2007).
Intracellular staining can be seen as an ‘‘x-ray’’, and is useful to
distinguish defective mobilization of pCD40L from absence of
stored pCD40L in cases where no mobilization of pCD40L is
observed.
(TIF)
Figure S2 pCD40L expression in splenic CD4+ T cell
subsets. A, Gating strategy for Treg cells, memory phenotype
(MP) and naive CD4
+ T cells. B–D, Mobilization of pCD40L upon
stimulation with PMA plus ionomycin and intracellular staining of
Figure 7. Severe inflammation does not compromise the lack
of expression of pCD40L by Treg cells. CNS infiltrating leukocytes
and splenocytes were obtained from EAE animals induced as Fig. 5A. A,
Gating strategy for cells from CNS and spleen. B&C , Intracellular CD40L
levels for effector CD4
+ T cells (B) and Treg cells (C). Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0031296.g007
Figure 6. CD4 SP thymocytes, but not Treg cells, store and mobilize pCD40L. A, Gating strategy for thymic nTreg cells and CD4 SP
thymocytes. B, Generation of in vivo iTreg cells. DO11.10 CD4
+ T cells were recovered from OVA- or BSA-fed recipient mice on day 6. C, Gating
strategy for in vivo iTreg cells and effector CD4
+ T cells. A BSA-fed mouse is shown as a negative control. D, thymic nTreg cells; E, CD4 SP thymocytes;
F, in vivo iTreg cells; and G, effector CD4
+ T cells, are analyzed by the mobilization assay and intracellular staining for pCD40L and CTLA-4. Data are
representative of three (D and E) or two (F and G) independent experiments.
doi:10.1371/journal.pone.0031296.g006
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PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31296Figure 8. CD4 SP thymocytes, but not CD8 SP or DP thymocytes, store and mobilize pCD40L. A, Gating strategy for identifying CD8 SP,
DP, and immature and mature CD4 SP thymocytes. B–E, Mobilization of pCD40L for immature (B) and mature (C) CD4 SP thymocytes, CD8 SP (D), and
DP (E) thymocytes. Cd40lg
2/2 : CD40L-deficient mouse. Data are representative of at least five independent experiments.
doi:10.1371/journal.pone.0031296.g008
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PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e31296Figure 9. iNKT cells possess and mobilize pCD40L. A, A fraction of the DN thymocyte population mobilizes pCD40L upon stimulation with PMA
plus ionomycin. B, pCD40L positive DN thymocytes are iNKT cells. C, iNKT deficient b2m2/2 mice lack the pCD40L positive DN thymocyte
population. D and F, Gating strategy for thymic (D) and splenic (F) iNKT cells. E and G, Mobilization of pCD40L in CD1d-tetramer-positive thymic (E)o r
splenic (G) iNKT cells upon stimulation with PMA plus ionomycin. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0031296.g009
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PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e31296Treg cells (B), MP (C) and naive (D) CD4
+ T cells. Data are
representative of seven independent experiments.
(TIF)
Figure S3 NK cells and CD8
+ T cells do not have
pCD40L. Gating strategies and the data for the mobilization of
pCD40L following stimulation with PMA plus ionomycin and
intracellular staining of pCD40L for NK cells (A) and
CD8
+CD44
hi T cells (B) are shown. Data are representative of
two independent experiments.
(TIF)
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